Search Results

You are looking at 1 - 10 of 10 items for :

  • "TERT promoter mutations" x
Clear All
Open access

Dario de Biase, Federica Torricelli, Moira Ragazzi, Benedetta Donati, Elisabetta Kuhn, Michela Visani, Giorgia Acquaviva, Annalisa Pession, Giovanni Tallini, Simonetta Piana and Alessia Ciarrocchi

. Mutations in the TERT promoter (26.5%) and in the BRAF gene (37.1%) showed the highest frequency within the entire set of samples analyzed ( Fig. 1A and B ). However, these two mutations showed a complementary trend with TERT promoter mutations

Open access

Huy Gia Vuong, Uyen N P Duong, Ahmed M A Altibi, Hanh T T Ngo, Thong Quang Pham, Hung Minh Tran, Greta Gandolfi and Lewis Hassell

described genetic marker, TERT promoter mutations, has shown promise in predicting patient’s outcomes ( 8 , 9 ). The prognostic implications of RAS mutations and RET/PTC rearrangements in PTC are still controversial. In the present study, we

Open access

Anello Marcello Poma, Riccardo Giannini, Paolo Piaggi, Clara Ugolini, Gabriele Materazzi, Paolo Miccoli, Paolo Vitti and Fulvio Basolo

lobectomy may be a sufficient treatment for low-risk FTC (i.e. MI-FTC with less than 4 vascular invasion foci) ( 12 ). However, molecular markers such as TERT promoter mutations were found to be an independent poor prognosis factor in differentiated

Open access

Ana P Estrada-Flórez, Mabel E Bohórquez, Alejandro Vélez, Carlos S Duque, Jorge H Donado, Gilbert Mateus, Cesar Panqueba-Tarazona, Guadalupe Polanco-Echeverry, Ruta Sahasrabudhe, Magdalena Echeverry and Luis G Carvajal-Carmona

stage ( 1 , 10 , 11 ), although the evidence is not consistent ( 12 , 13 , 14 ). Hence, BRAF V600E on its own has limited utility as a prognosis PTC biomarker. More recently, two TERT promoter mutations, C228T and C250T, were found in ~10% of PTC

Open access

Huy Gia Vuong, Nguyen Phuoc Long, Nguyen Hoang Anh, Tran Diem Nghi, Mai Van Hieu, Le Phi Hung, Tadao Nakazawa, Ryohei Katoh and Tetsuo Kondo

significantly higher as compared to classical PTC. The more recently discovered TERT promoter mutations were also more prevalent in TCVPTCs than in classical PTCs ( 9 , 29 ). The association of BRAF and TERT promoter mutations with a poor outcome in PTC

Open access

Guoquan Zhu, Yuying Deng, Liqin Pan, Wei Ouyang, Huijuan Feng, Juqing Wu, Pan Chen, Jing Wang, Yanying Chen and Jiaxin Luo

metastasis. In recent years, an increasing number of molecular genetic characteristics associated with invasiveness and clinical management have been uncovered, including the BRAF V600E mutation, TERT promoter mutations, RAS mutations and RET

Open access

Barbora Pekova, Sarka Dvorakova, Vlasta Sykorova, Gabriela Vacinova, Eliska Vaclavikova, Jitka Moravcova, Rami Katra, Petr Vlcek, Pavla Sykorova, Daniela Kodetova, Josef Vcelak and Bela Bendlova

E and absence of tert promoter mutations characterize sporadic pediatric papillary thyroid carcinomas in Japan . Endocrine Pathology 2017 28 . ( ) 28176151 10 Hay ID Gonzalez-Losada T Reinalda

Open access

Catarina Tavares, Maria João Coelho, Catarina Eloy, Miguel Melo, Adriana Gaspar da Rocha, Ana Pestana, Rui Batista, Luciana Bueno Ferreira, Elisabete Rios, Samia Selmi-Ruby, Bruno Cavadas, Luísa Pereira, Manuel Sobrinho Simões and Paula Soares

BRAF , NRAS and TERT promoter mutations ( TERT p) had been reported previously; mutations were screened as previously described ( 32 , 33 , 34 ). RNA extraction and reverse transcription Total RNA was extracted from tumors and from

Open access

Tiemo S Gerber, Arno Schad, Nils Hartmann, Erik Springer, Ulrich Zechner and Thomas J Musholt

promoter mutations in papillary thyroid carcinomas in a BRAF(V600E) mutation-prevalent population . Thyroid 2016 26 901 – 910 . ( ) 10.1089/thy.2015.0488 13 McFadden DG Vernon A Santiago PM

Open access

Changjiao Yan, Meiling Huang, Xin Li, Ting Wang and Rui Ling

R Liu X Murugan AK Zhu G Zeiger MA Pai S Bishop J . BRAF V600E and tert promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence . Journal of Clinical Oncology 2014 32 . ( https